NautaDutilh assisted Arvelle Therapeutics on its acquisition by Angelini Pharma
NautaDutilh assisted biotech company Arvelle Therapeutics alongside Sidley Austin on its acquisition by Italian Biotech Angelini Pharma. The deal is the largest acquisition for the 100-year old Angelini. Quoting both its CEO and executive vice president: “It’s the most important investment in the history of our Group”.
Angelini Pharma will acquire Arvelle in an all cash transaction for a total aggregate valuation of up to USD 960 million. Following customary regulatory approval, an amount of USD 610 million will be paid. Subsequently, and subject to reaching certain revenue targets, a further USD 350 million will be paid.
NautaDutilh has acted as Arvelle' s Dutch counsel since its inception in 2019 and also advised Arvelle on its Series A Investment. In that investment round Arvelle received one of the largest initial financing commitments for an European-focused biopharmaceutical company from a global syndicate of investors that include NovaQuest, LSP, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners.